Board of Trustees

Our Board of Trustees is responsible for the strategic management of the organisation and delivery of our charitable objectives. It also has a legal responsibility to ensure the charity complies with current legislation and governance best practice.

Our Trustees are not remunerated, they hold voluntary posts. Our Board is made up of very experienced and talented people, many of whom have a direct personal
understanding of the effects of inherited sight loss.

Don Grocott

Don Grocott TD MA FRSA FIoD

Chair

Don Grocott, Chairman, was appointed to the Board in early 2009 and as
Chairman in June 2011. He has extensive experience in management consultancy and business. He has worked in the optical sector both in management and in key positions in various representative bodies.

Don sits on a number of Boards and is the director of an enterprise to help
patients in private healthcare and a small cancer research charity. He joined the Reserve Army when he was 18 and currently is the honorary colonel of a
yeomanry squadron.

janet crookes

Janet Crookes BA FCA

Treasurer

Janet joined the Board in 2012.

With 17 years’ experience as a partner at Grant Thornton UK LLP, Janet has
amassed a wealth of experience in strategic, financial and people management
and has spent much of that time working with charities of all shapes and sizes.

Her son was diagnosed with retinitis pigmentosa in 2007 at the age of 15 and
Janet’s husband Phil has since been involved in fundraising for the charity.

Janet calls upon both her personal and professional experience in her trustee
role.

Fundraising

Make a Donation

Each and every contribution makes a difference, and our friendly fundraising team would love
to hear from you if you have a question or want to get involved. Just call us on
01280 815900 or email fundraising@RetinaUK.org.uk

cyclists at eiffel tower

Mark Baxter – Reflections in a Broken Retina

My name is Mark Baxter and from an early age I was diagnosed with a deteriorating retinal eye condition called Retinitis Pigmentosa or RP for short,
which will slowly lead to blindness.

With no night vision and very limited peripheral vision I can appreciate how emotionally and physically frustrating living, learning and working

We are
RetinaUK

retina international logo

RP Fighting Blindness is a member of Retina International (RI) and in fact were one of several charities
from around the world which worked together to create the organisation in 1978. RI now brings
together over 40 national organisations working in their respective countries to fight retinitis
pigmentosa and other retinal dystrophies.

RetinaUK Membership

Join us in our fight to find a cure for retinitis pigmentosa.

By joining as a member you will also strengthen RetinaUK, because the more members we have, the more representative of people with RP and thier families we will be.

Types of
bequest

There are three types of bequest you could leave to a Retina UK:

  • Pecuniary – this is a specific sum of money. Bear in mind that inflation could cause the value of a pecuniary bequest to lessen over time, so you might want to consider asking your solicitor to index link the gift, preserving its value.
  • Residuary – this is a share of your remaining estate after all debts and expenses have been discharged and all pecuniary and specific bequests have been paid.
  • Specific – you may have a particular item you wish to leave to the charity, perhaps some jewellery, artwork, furniture or even something larger such as a car or house.

How to
word the
legacy

Your solicitor will be able to advise you on the wording to use to ensure that your wishes are made clear. It is important to use the charity’s full name, address and registered charity number to make sure that your gift reaches us: Retina UK, PO Box 350, Buckingham,

Inheritance
tax

Currently, the threshold at which inheritance tax is payable is £325,000. The rate is 40%, but if you leave 10% or more of your estate to a charity, the rate reduces to 36%. This means that by including a charitable bequest you may be able to reduce the tax burden on your other beneficiaries. Charitable bequests are exempt from inheritance tax.

Informing
us about
your gift

Preparing your will is a very personal matter and there is no  requirement for you to inform Retina UK of your intentions. However, we would love the opportunity to thank you for remembering us in such an important way, so please do get in touch with our Senior Fundraising Manager Deborah on 01280 815900 or email Deborah@RetinaUK.org.uk if you would like to share your decision with us.

Including a gift of any size is a fantastic way to support our vital
work and ensure that we can be here for the ever increasing
numbers of people who need our help. Your contribution could
also fund ground-breaking discoveries in the rapidly changing field
of research, leading to the development of viable treatments for
people with inherited progressive sight loss.

Use the links LOCATION to find out more about remembering
Retina UK in your will. Alternatively, call our Senior Fundraising
Manager Deborah on 01280 815900 for an informal and
confidential chat, or email Deborah@RetinaUK.org.uk.

We recommend that you instruct a qualified solicitor to prepare
your will and you can find a comprehensive list of firms on the Law
Society website. You may also want to take a look at The Goodwill
Partnership who can visit you at home (if you live in England or
Wales) to draw up a solicitor-provided will.

If you have already included a gift to the charity in your will, then
we are enormously grateful. You don’t have to tell us about your
decision, but we would love the opportunity to thank you
personally, so do get in touch.

Please note that Retina UK does not endorse any particular firm or
firms. We recommend that you conduct your own research to
identify the solicitor or provider who best meets your
requirements.

“Including a gift of any
size is a fantastic way
to support our vital
work and ensure that
we can be here for the
ever increasing “

– Someones Name

Side Bar Samples

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas varius tortor nibh,
sit amet tempor nibh finibus et. Aenean eu enim justo. Vestibulum aliquam hendrerit

New Header Style

Side Bar Samples

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas varius tortor nibh,
sit amet tempor nibh finibus et. Aenean eu enim justo. Vestibulum aliquam hendrerit

Mark Baxter and his wife in pub garden

Day 1: London to Calais
Our challenge begins bright and early from Crystal Palace heading south en route to the coast. (Distance: approx 95 miles)

Day 2: Calais to Abbeville
La belle France! Stunning picturesque countryside awaits us in northern France as we travel south. (Distance: approx 75 miles)

Day 3: Abbeville to Beauvais
Our route this morning follows the river Somme out of Abbeville. (Distance: approx 70 miles

Day 4: Beauvais to Paris
Our final day of cycling and the big push to Paris, our final destination. (Distance: approx 60 miles)

Day 5: Paris to London
The day is yours to soak up the Parisian way of life and explore the city. Eurostar home, arriving at St Pancras.

To find out more and to register for this amazing challenge, please click on the link below.

https://londonparisbikeride.co.uk/whats-it-like.aspx?charity=62673

Man smiling

“This is the best event I Have ever taken part in. If you are thinking about doing it…do it! “

PULL QUOTE

“Fusce vehicula dolor arcu,
sit amet blandit dolor
mollis nec. Donec viverra
eleifend lacus, vitae
ullamcorper metus.”

“Fusce vehicula dolor arcu,
sit amet blandit dolor
mollis nec. Donec viverra
eleifend lacus, vitae
ullamcorper metus.”

LISTS

  • Unordered List – Lorem ipsum dolor
  • Sit amet, consectetur adipiscing elit. Ut pretium pretium tempor.
  • Ut eget imperdiet neque
  • In volutpat ante semper
  • Molestie, et aliquam erat laoreet
  • Sed sit amet arcu aliquet, molestie justo at, auctor nunc.
  1. Unordered List – Lorem ipsum dolor
  2. Sit amet, consectetur adipiscing elit. Ut pretium pretium tempor.
  3. Ut eget imperdiet neque
  4. In volutpat ante semper
  5. Molestie, et aliquam erat laoreet
  6. Sed sit amet arcu aliquet, molestie justo at, auctor nunc.

IMAGE WITH CAPTION

Image Caption

FAQS

It can take many years and millions of pounds to develop a new
treatment from start to finish. Even after laboratory studies and
tests in animal models are complete, most new treatments have
to go through a series of clinical trials to prove that they are
acceptably safe and offer meaningful benefit. Each one of these
trials can take a few years by the time participants are recruited,
treated and followed up and all the data is analysed.
However, this is real optimism that treatments for inherited sight
loss may start to become available in the next decade. Our
website has more information about the treatment approaches
being explored. (link to approaches to treatment home)
Successful therapy may eventually depend on a combination of
these.

It can take many years and millions of pounds to develop a new
treatment from start to finish. Even after laboratory studies and
tests in animal models are complete, most new treatments have
to go through a series of clinical trials to prove that they are
acceptably safe and offer meaningful benefit. Each one of these
trials can take a few years by the time participants are recruited,
treated and followed up and all the data is analysed.
However, this is real optimism that treatments for inherited sight
loss may start to become available in the next decade. Our
website has more information about the treatment approaches
being explored. (link to approaches to treatment home)
Successful therapy may eventually depend on a combination of
these.

It can take many years and millions of pounds to develop a new
treatment from start to finish. Even after laboratory studies and
tests in animal models are complete, most new treatments have
to go through a series of clinical trials to prove that they are
acceptably safe and offer meaningful benefit. Each one of these
trials can take a few years by the time participants are recruited,
treated and followed up and all the data is analysed.
However, this is real optimism that treatments for inherited sight
loss may start to become available in the next decade. Our
website has more information about the treatment approaches
being explored. (link to approaches to treatment home)
Successful therapy may eventually depend on a combination of
these.

It can take many years and millions of pounds to develop a new
treatment from start to finish. Even after laboratory studies and
tests in animal models are complete, most new treatments have
to go through a series of clinical trials to prove that they are
acceptably safe and offer meaningful benefit. Each one of these
trials can take a few years by the time participants are recruited,
treated and followed up and all the data is analysed.
However, this is real optimism that treatments for inherited sight
loss may start to become available in the next decade. Our
website has more information about the treatment approaches
being explored. (link to approaches to treatment home)
Successful therapy may eventually depend on a combination of
these.

It can take many years and millions of pounds to develop a new
treatment from start to finish. Even after laboratory studies and
tests in animal models are complete, most new treatments have
to go through a series of clinical trials to prove that they are
acceptably safe and offer meaningful benefit. Each one of these
trials can take a few years by the time participants are recruited,
treated and followed up and all the data is analysed.
However, this is real optimism that treatments for inherited sight
loss may start to become available in the next decade. Our
website has more information about the treatment approaches
being explored. (link to approaches to treatment home)
Successful therapy may eventually depend on a combination of
these.

It can take many years and millions of pounds to develop a new
treatment from start to finish. Even after laboratory studies and
tests in animal models are complete, most new treatments have
to go through a series of clinical trials to prove that they are
acceptably safe and offer meaningful benefit. Each one of these
trials can take a few years by the time participants are recruited,
treated and followed up and all the data is analysed.
However, this is real optimism that treatments for inherited sight
loss may start to become available in the next decade. Our
website has more information about the treatment approaches
being explored. (link to approaches to treatment home)
Successful therapy may eventually depend on a combination of
these.

It can take many years and millions of pounds to develop a new
treatment from start to finish. Even after laboratory studies and
tests in animal models are complete, most new treatments have
to go through a series of clinical trials to prove that they are
acceptably safe and offer meaningful benefit. Each one of these
trials can take a few years by the time participants are recruited,
treated and followed up and all the data is analysed.
However, this is real optimism that treatments for inherited sight
loss may start to become available in the next decade. Our
website has more information about the treatment approaches
being explored. (link to approaches to treatment home)
Successful therapy may eventually depend on a combination of
these.

It can take many years and millions of pounds to develop a new
treatment from start to finish. Even after laboratory studies and
tests in animal models are complete, most new treatments have
to go through a series of clinical trials to prove that they are
acceptably safe and offer meaningful benefit. Each one of these
trials can take a few years by the time participants are recruited,
treated and followed up and all the data is analysed.
However, this is real optimism that treatments for inherited sight
loss may start to become available in the next decade. Our
website has more information about the treatment approaches
being explored. (link to approaches to treatment home)
Successful therapy may eventually depend on a combination of
these.

Sample Gallery